Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Denali Therapeutics Inc. (DNLI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/08/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights"
05/08/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights"
02/27/2023 8-K Quarterly results
Docs: "Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights"
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases"
11/03/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
10/18/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors SOUTH SAN FRANCISCO, Calif., March 15, 2022 — Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases, today announced that Steve Krognes will transition from his role as Chief Financial Officer and join the company's Board of Directors on May 1, 2022. Denali's Chief Operating Officer Alexander Schuth, M.D., will add the Chief Financial Officer role to his current responsibilities, becoming Denali's Chief Operating and Financial Officer. “We are deeply grateful for Steve's major impact at Denali over his six years as Denali'..."
02/28/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
02/14/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces Continued Progress in DNL310 Program for MPS II Supporting Planned Initiation of Phase 2/3 Clinical Trial"
02/07/2022 8-K Appointed a new director
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022"
11/17/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593"
11/04/2021 8-K Quarterly results
Docs: "Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights"
08/04/2021 8-K Quarterly results
07/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS in Patients with the Lysosomal Storage Disease Hunter Syndrome"
06/04/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
02/10/2021 8-K/A Quarterly results
02/05/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/10/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle"
10/07/2020 8-K Quarterly results
08/20/2020 8-K Quarterly results
08/20/2020 8-K/A Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy